14-day Premium Trial Subscription Sign Up For FreeGet Free

Anthera Pharmaceuticals Stock Forecast NASDAQ:ANTH

$0.000001 (0%)

Volume: 0

Closed: Jan 21, 2022

Hollow Logo Score: 0.000

Anthera Pharmaceuticals Stock Forecast

$0.000001 (0%)

Volume: 0

Closed: Jan 21, 2022

Score Hollow Logo 0.000

Anthera Pharmaceuticals Company Profile

25801 Industrial Boulevard

Hayward CA 94545



Anthera Pharmaceuticals


Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The company’s Phase III product candidates include liprotamase or Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, and others. It also develops Blisibimod, which is in Phase II clinical study for the treatment of Immunoglobulin A nephropathy. The company was founded in 2004 and is headquartered in Hayward, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE